Grainne O'Kane

OPTIMUM rand ph2 adv #BTC
➡️dx control on plat- olaparib v olaparib/durva
➡️somatic/ germline DDR but wide range genes
➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm)
❎no diff 6mth PFS
❎1yr OS rate 64 v76%
❗️we must define true HRD in trials & understand TME
@myESMO #ESMO26 @OncoAlert

Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE
➡️mPFS 14.6 v 10.2 HR 0.7
➡️ORR 71 v 49% by mRECIST
❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx
❎much higher gd3/4 TRAEs 71%v31%
➡️❗️1/3 BCLCA
➡️Role combo unclear consistent -ve OS
@myESMO #ESMO26 @OncoAlert

🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1)
➡️two cohorts n=60 #PDAC
➡️safety- mainly haem, none precluded surgery
➡️ORR 63% & 87%;MPR in 17%
➡️R0 resection rate 100%
✅6 mth EFS rate 87% & 96%
➡️100% ⬇️CA19.9; OS pending
@myESMO #ESMO26 @OncoAlert

INCB161734 KRASG12D (ON/OFF) + GnP or mFFX; updated ph1, n=53
➡️mostly GI toxicity,dose intensity 85% with GnP & 77%mFFX
✅ORR 69%, DCR 96% GnP
✅ORR 89%, DCR 100% mFFX
➡️6 mth PFS rates 80% & 90%
⭐️impressive & can combine mFFX
✅DAWN-303 ph3 ongoing
@myESMO #ESMO26 @OncoAlert

🔥HARMONi-GI1 ph3 advanced #BTC
➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim
✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths
✅mOS 14.9 v12.1mths HR0.75
➡️AE rate high in both
Control arm OS represents❗️VEGF in BTC ⭐️ looks promising
@myESMO #ESMO26 @OncoAlert